Cardiogen (20mg Vial) Dosage Protocol
Khavinson cardiovascular short-peptide bioregulator (AEDR) — research-only; not FDA/EMA approved, benefits unproven.
Why Cardiogen draws research interest
These are the directions researchers and the peptide community most often explore Cardiogen for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Cardiovascular support
The primary reason people seek it; studied in Khavinson bioregulator research on cardiovascular function — preclinical, benefits unproven.
Heart tissue & myocardium
Explored in animal research as an AEDR (Ala-Glu-Asp-Arg) short peptide acting on cardiac muscle cells; not FDA/EMA approved.
Vascular & endothelial health
Investigated in preclinical studies for effects on blood-vessel and endothelial cells; investigational, benefits unproven.
Aging & longevity
Researched as a Khavinson geroprotective peptide bioregulator in animal-only aging studies; not approved for any use.
Research context, not medical advice. Nothing here says Cardiogen treats, cures, or improves any condition. Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Mix & measure Cardiogen · 20 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
Cardiogen is a synthetic short-peptide bioregulator — the tetrapeptide Ala-Glu-Asp-Arg (AEDR) — one of the Khavinson “cytogen” peptides developed at the St. Petersburg Institute of Bioregulation & Gerontology and marketed as a heart/cardiovascular bioregulator[1][2]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine; all proposed cardiovascular benefits are unproven and supported only by preclinical data — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 20 mg vial → ~6.67 mg/mL (6,667 mcg/mL), giving accurate small-dose measurement.
200–500 mcg once daily, titrated upward gradually across a 12-week course (about ~2–3.5 mg per week).
At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg; 200 mcg ≈ 3 units and 500 mcg ≈ 7.5 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 20 mg vial → final concentration ~6.67 mg/mL (6,667 mcg/mL).
Typical daily range: 200–500 mcg once daily, raised gradually over a 12-week course.
Easy measuring: At ~6.67 mg/mL, 1 unit ≈ 66.7 mcg on a U-100 syringe. Because doses are small (3–7.5 units), a 30- or 50-unit syringe gives the best measuring accuracy.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, titrating up as tolerated. Across the 12-week cycle the daily dose climbs from 200 mcg to 500 mcg (a weekly total of roughly 1.4–3.5 mg)[3]. These figures reflect typical short-peptide bioregulator schedules, not approved human dosing.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution is deliberately large so each dose reads at 30 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with gradual titration.
One 20 mg vial holds enough for several weeks of dosing, but the reconstituted solution should be used within ~28 days, so plan about one vial per month.
- 8 weeks: ~2 vials
- 12 weeks: ~3 vials
- 16 weeks: ~4 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 20 mg vial for reconstitution.
- 8 weeks (2 vials): ~6 mL → 1 bottle
- 16 weeks (4 vials): ~12 mL → 1–2 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Protocol Overview
A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.
- ▪Goal: Cardiogen is proposed as a cardiovascular bioregulator intended to support heart-tissue function — a hypothesis based on preclinical (cell-culture and animal) data, not established in humans[4][5].
- ▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
- ▪Dose Range: 200–500 mcg per day with gradual titration over 12 weeks.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 20 mg vial gives ~6.67 mg/mL for accurate unit measurements.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A suggested daily titration approach based on common reference doses.
- ▪Start: Begin at 200 mcg once daily to gauge tolerability.
- ▪Titrate: Increase by roughly 100 mcg every two weeks as tolerated.
- ▪Target: Reach about 400–500 mcg daily by weeks 5–12.
- ▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides.
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy.
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Cardiogen is not FDA/EMA-approved for human use (in Russia it is handled as a supplement-type bioregulator, not an approved drug); WADA lists no specific entry, but the S0 “non-approved substances” catch-all applies to athletes[7].
How This Works
Cardiogen is a synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Arg (AEDR) — one of the Khavinson “cytogen” short peptides developed at the St. Petersburg Institute of Bioregulation & Gerontology and marketed as a heart/cardiovascular bioregulator[1][2].
The originators’ proposed mechanism is that the short peptide enters the cell nucleus, binds promoter regions of DNA, and alters tissue-specific gene expression — in this case favouring cardiomyocyte function and reducing cell apoptosis. This gene-regulation hypothesis is the developers’ own model, not an independently established mechanism, and all supporting evidence is preclinical[3][4].
Preclinical reports from the originating group describe effects on cardiomyocytes in cell culture and in rat/rabbit models, including reduced apoptosis and improved markers of cardiac-tissue function[5]. These findings have not been independently replicated in high-quality studies.
Important caveat: there are no high-quality independent human randomized trials of Cardiogen. The cardioprotective, “genetic-repair” and rejuvenation claims associated with the Khavinson bioregulators rest on the originators’ preclinical work and should be read as unproven hypotheses, not established benefits.
Cardiogen is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
General habits that support cardiovascular health alongside the protocol.
- ▪Nutrition: Favour a balanced, heart-healthy diet with sensible sodium intake.
- ▪Activity & rest: Pair regular moderate activity with adequate rest, in line with general cardiovascular guidance.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What preclinical and veterinary literature describe; human evidence is limited and individual results vary.
Potential Benefits
- ▪Cardiac markers (preclinical): The originators’ cell-culture and rat/rabbit studies report reduced cardiomyocyte apoptosis and improved cardiac-tissue markers[4][5].
- ▪Gene-expression hypothesis (preclinical): Proposed to bind promoter DNA and shift tissue-specific gene expression — the developers’ model, unverified independently[3].
- ▪Tolerability (limited data): Reported as generally well tolerated in the small preclinical literature, with occasional mild injection-site reactions; human safety data are sparse.
- ▪Note on humans: These benefits are not established in humans — no high-quality independent human RCTs of Cardiogen have been completed[6].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport restriction: As an unapproved substance, Cardiogen falls under the WADA S0 catch-all and is not permitted for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance.
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully.
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin).
- ▪Skip aspiration for subcutaneous shots — it isn’t needed.
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy.
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Khavinson VK — Peptides and AgeingReview of the Khavinson short-peptide (cytogen/cytomax) bioregulators developed at the St. Petersburg Institute of Bioregulation & Gerontology.
- 2
PubMed — AEDR / Cardiogen peptideLiterature on the cardiovascular short peptide Ala-Glu-Asp-Arg (AEDR) marketed as Cardiogen.
- 3
Khavinson VK et al. — Peptide regulation of gene expressionProposed mechanism: short peptides binding promoter DNA and modulating tissue-specific gene expression (originators’ hypothesis).
- 4
Preclinical cardiomyocyte studies (PubMed)Cell-culture and animal reports describing short-peptide effects on cardiomyocytes and apoptosis; not independently replicated.
- 5
Animal models of cardiovascular peptide bioregulatorsRat/rabbit studies of cardiovascular short peptides reported by the originating group; preclinical evidence only.
- 6
ClinicalTrials.govTrial registry search — no completed high-quality human efficacy trials of Cardiogen (AEDR).
- 7
WADA Prohibited ListS0 “non-approved substances” catch-all covering unapproved agents such as Cardiogen for athletes.
How to reconstitute Cardiogen
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the Cardiogen vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
Cardiogen — frequently asked questions
How do I reconstitute a 20 mg vial of Cardiogen?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Cardiogen?
There is no single correct amount — more water simply spreads the same 20 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Cardiogen after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 20 mg vial of Cardiogen provide?
Divide the vial strength of 20 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Cardiogen approved for human use?
No. Cardiogen is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.